FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics

FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.

FDA Rejects Rocket Pharmaceuticals’ Gene Therapy for Ultra-Rare Immune Disease, Requests Additional Manufacturing Information

FDA, Rocket Pharmaceuticals, Gene Therapy, Leukocyte Adhesion Deficiency-I (LAD-I), Manufacturing Information, Complete Response Letter

Progentos Secures $65 Million for Groundbreaking Remyelination Therapy in Multiple Sclerosis Treatment

Progentos, funding, remyelination therapy, multiple sclerosis, MS treatment, clinical trials, neurodegenerative diseases, nervous system repair, biotechnology.